Human Genome Epidemiology Literature Finder
Records 1 - 11 (of 11 Records) |
Query Trace: Disease Progression and ABL1[original query] |
---|
BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assay. Leukemia research 2011 1 35 (5): 598-603. Ono Takaaki, Miyawaki Shuichi, Kimura Fumihiko, Kanamori Heiwa, Ohtake Shigeki, Kitamura Kunio, Fujita Hiroyuki, Sugiura Isamu, Usuki Kensuke, Emi Nobuhiko, Tamaki Shigehisa, Aoyama Yasutaka, Kaya Hiroyasu, Naoe Tomoki, Tadokoro Kenichi, Yamaguchi Toshikazu, Ohno Ryuzo, Ohnishi Kazunori, |
Incidence and clinical importance of BCR-ABL1 mutations in Iranian patients with chronic myeloid leukemia on imatinib. Journal of human genetics 2015 Mar . Rostami Golale, Hamid Mohammad, Yaran Majid, Khani Mohsen, Karimipoor Morte |
Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1(35INS). Leukemia research 2016 Oct 49 108-12. Berman Ellin, Jhanwar Suresh, Hedvat Cyrus, Arcila Maria E, Wahab Omar Abdel-, Levine Ross, Maloy Molly, Ma Wanlong, Albitar Mah |
Analysis of clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2017 Oct . Zilberg Catherine, Lee Matthew Weicai, Yu Bing, Ashford Bruce, Kraitsek Spiridoula, Ranson Marie, Shannon Kerwin, Cowley Mark, Iyer N Gopalakrishna, Palme Carsten E, Ch'ng Sydney, Low Tsu-Hui Hubert, O'Toole Sandra, Clark Jonathan R, Gupta Ru |
Integrative Genomic Analysis Reveals Cancer-Associated Gene Mutations in Chronic Myeloid Leukemia Patients with Resistance or Intolerance to Tyrosine Kinase Inhibitor. OncoTargets and therapy 2020 9 13 8581-8591. Wu Waner, Xu Na, Zhou Xuan, Liu Liang, Tan Yaxian, Luo Jie, Huang Jixian, Qin Jiayue, Wang Juan, Li Zhimin, Yin Changxin, Zhou Lingling, Liu Xiao |
The Prognostic Significance of TET2 Single Nucleotide Polymorphism in Egyptian Chronic Myeloid Leukemia. Mediterranean journal of hematology and infectious diseases 2020 12 (1): e2020004. Hamed Nahla A, Elhalawani Nabil A, Kassem Heba S, Ayad Mona W, Dammag Enas |
Clinical and Molecular Attributes of Patients With BCR/ABL1-negative Myeloproliferative Neoplasms in India: Real-world Data and Challenges. Clinical lymphoma, myeloma & leukemia 2021 3 21 (6): e569-e578. Singh Suvir, Kaur Komalpreet, Paul Davinder, Jain Kunal, Singh Jagdeep, Narang Vikram, Garg Bhavna, Sood Neena, Dhillon Barjinderj |
Genomic Alteration Spectrum of Non-Small Cell Lung Cancer Patients in East-China Characterized by Tumor Tissue DNA and Cell-Free DNA. OncoTargets and therapy 2022 5 15 571-584. Li Jie, Chen Siwen, Xue Hui, Wang Haoyi, Huang Tianwei, Xie Hongya, He Jiang, Ke Cai, Yu Zhaonan, Ni B |
BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia. Blood science (Baltimore, Md.) 2022 12 4 (4): 199-204. Zhang Yanqing, Bi Hailiang, Wang Ying, Chen Long, Pan Jiaqi, Xu Ping, Wang Wei, Yang Shaob |
Targeted Next-Generation Sequencing Identifies Additional Mutations Other than BCR?ABL in Chronic Myeloid Leukemia Patients: A Chinese Monocentric Retrospective Study. Cancers 2022 12 14 (23): . Hu Shiwei, Chen Dan, Xu Xiaofei, Zhang Lan, Wang Shengjie, Jin Keyi, Zheng Yan, Zhu Xiaoqiong, Jin Jie, Huang Ji |
Exposure-Efficacy Analysis of Asciminib in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase. Clinical pharmacology and therapeutics 2022 Jul . Combes François Pierre, Li Ying Fei, Hoch Matthias, Lorenzo Sebastien, Ho Yu-Yun, Sy Sherwin K |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: